Publicaciones
-
Gassiot S, González Y, Morgades M, Motlló C, Clapés V, Maluquer C, Ibarra G, Abril L, Ribera JM and Oriol A.
Response to first cycle is the major predictor of long term response to lenalidomide and dexamethasone therapy in relapsed and refractory multiple myeloma: can we spare patients the toxicity and costs of additional agents?
Clinical Lymphoma, Myeloma and Leukemia . : . Nº de citas: 2
-
Martinez-Monseny T, Bolasell M, Callejón L, Cuadras-Palleja D, Freniche V, Itzep DC, Gassiot S, Arango P, Casas-Alba D, de la Morena E, Corral J, Montero-Sanchez R, Pérez-Cerdá C, Pérez-Dueñas B, Artuch-Iriberri R, Jaeken J, and the CDG Spanish Consortium and Serrano M.
AZATAX: Acetazolamide safety and efficacy in cerebellar syndrome in PMM2 congenital disorder of glycosylation (PMM2-CDG)
ANNALS OF NEUROLOGY . 85(5): 740-751. Nº de citas: 52
-
Vega-García N, Malatesta R, Estella-Aguado MC, Pérez-Jaume S, Esperanza-Cebollada E, Torrebadell-Burriel M, Català-Temprano A, Gassiot S, Berrueco R, Ruiz-Llobet A, Alonso-Saladrigues A, Mesegue-Meda M, Pont-Martí S, Rives-Solà S and Camós-Guijosa M.
Paediatric patients with acute leukaemia and KMT2A (MLL) rearrangement show a distinctive expression pattern of histone deacetylases
BRITISH JOURNAL OF HAEMATOLOGY . 182(4): 542-553. Nº de citas: 7
-
Gassiot S, Motlló C, Llombart I, Morgades M, González Y, Garcia-Caro M, Ribera JM and Oriol A.
Impact of induction treatment before autologous stem cell transplantation on long-term outcome in patients with newly diagnosed multiple myeloma
EUROPEAN JOURNAL OF HAEMATOLOGY . 98(6): 569-576. Nº de citas: 3
-
Sorigue M, Juncà J, Gassiot S, Millá F, Mate JL and Navarro JT.
A Case of CD138-/CD19+/CD4+IgD Plasma Cell Leukemia
CYTOMETRY PART B-CLINICAL CYTOMETRY . 88(1): 69-73. Nº de citas: 2